BLRX

$0.00

(

0.00%

)
Quote details

stock

BioLineRx Ltd

NASDAQ | BLRX

3.81

USD

$0.00

(

0.00%

)

At Close (As of Oct 16, 2025)

$16.95M

Market Cap

-

P/E Ratio

-6

EPS

$22.40

52 Week High

$2.29

52 Week Low

HEALTHCARE

Sector

BLRX Chart

Recent Chart
Price Action

BLRX Technicals

Tags:

BLRX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $20M
Total Revenue $29M
Cost Of Revenue $9.3M
Costof Goods And Services Sold $9.3M
Operating Income -$20M
Selling General And Administrative $18M
Research And Development $9.1M
Operating Expenses $40M
Investment Income Net -
Net Interest Income -$7.3M
Interest Income $1.8M
Interest Expense $9.1M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $4.1M
Income Before Tax -$9.2M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$9.2M
Comprehensive Income Net Of Tax -
Ebit -$147K
Ebitda $3.9M
Net Income -$9.2M

Revenue & Profitability

Earnings Performance

BLRX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $39M
Total Current Assets $27M
Cash And Cash Equivalents At Carrying Value $10M
Cash And Short Term Investments $10M
Inventory $3.1M
Current Net Receivables $3.9M
Total Non Current Assets $12M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $10M
Intangible Assets Excluding Goodwill $10M
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $9.1M
Other Current Assets $534K
Other Non Current Assets -
Total Liabilities $25M
Total Current Liabilities $15M
Current Accounts Payable $5.6M
Deferred Revenue -
Current Debt -
Short Term Debt $5M
Total Non Current Liabilities $10M
Capital Lease Obligations $1.6M
Long Term Debt $9M
Current Long Term Debt $4.5M
Long Term Debt Noncurrent -
Short Long Term Debt Total $15M
Other Current Liabilities $4.8M
Other Non Current Liabilities -
Total Shareholder Equity $13M
Treasury Stock -
Retained Earnings -$400M
Common Stock $38M
Common Stock Shares Outstanding $80M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$44M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $4.1M
Capital Expenditures $54K
Change In Receivables -
Change In Inventory -$1.2M
Profit Loss -
Cashflow From Investment $29M
Cashflow From Financing $21M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$9.2M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $20M
Total Revenue $29M
Cost Of Revenue $9.3M
Costof Goods And Services Sold $9.3M
Operating Income -$20M
Selling General And Administrative $18M
Research And Development $9.1M
Operating Expenses $40M
Investment Income Net -
Net Interest Income -$7.3M
Interest Income $1.8M
Interest Expense $9.1M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $4.1M
Income Before Tax -$9.2M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$9.2M
Comprehensive Income Net Of Tax -
Ebit -$147K
Ebitda $3.9M
Net Income -$9.2M

BLRX News

BLRX Profile

BioLineRx Ltd Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

BioLineRx Ltd. is a clinical-stage biopharmaceutical company based in Hevel Modi'in, Israel, dedicated to developing innovative therapies for oncology and other serious health conditions. The company boasts a diverse pipeline of promising candidates that target significant unmet medical needs in cancer treatment, highlighting its commitment to advancing research and development. Leveraging cutting-edge technologies and strategic collaborations, BioLineRx aims to enhance patient outcomes while delivering value for investors, positioning itself as a key player in the biopharmaceutical industry.

VHAI
-20.00%
$0.00
VIVK
+4.67%
$0.30
YYAI
-10.71%
$0.12
BURU
+1.07%
$0.34
EPWK
+26.46%
$0.09
NVDA
-0.11%
$179.83
BITF
-18.39%
$5.28
RXRX
-7.21%
$6.29
CGBS
-39.47%
$0.03
IVF
+153.11%
$1.90
PLUG
-8.70%
$3.51
ADAP
+6.57%
$0.19
BYND
-22.39%
$0.52
YDKG
-54.14%
$0.08
NVTS
+3.10%
$15.63
RGTI
-14.85%
$47.97
DNN
-2.83%
$3.08
LAES
-2.09%
$7.49
NIO
-1.09%
$6.74
MIRA
+49.24%
$1.97
SCNX
-20.41%
$0.56
F
-0.27%
$11.72
BBD
+1.71%
$3.25
WHWK
+27.64%
$2.68
ACHR
-8.90%
$11.87
TLRY
-8.33%
$1.54
KVUE
-13.43%
$14.07
TSLA
-1.47%
$428.75
ONDS
-13.77%
$8.19
IONZ
+18.46%
$3.41
AXDX
-61.36%
$0.03
INTC
-1.10%
$36.74
ETHD
+6.47%
$3.78
DFLI
-32.52%
$1.32
CAN
-14.28%
$1.68
HPE
-10.09%
$22.51
AMD
-1.33%
$235.40
SOFI
-6.13%
$26.31
GDXD
-7.91%
$0.61
RIG
-3.00%
$3.21
MARA
-11.62%
$20.18
CLF
-3.39%
$13.47
GNPX
-43.15%
$0.47
BTG
+3.96%
$5.89
FEMY
+33.89%
$0.73
VSEE
-8.56%
$0.54
BTBT
-8.99%
$3.69
AAL
-6.00%
$11.75
RR
-7.95%
$5.67
GPUS
-6.14%
$0.36
LGCB
+19.39%
$1.97
NAK
-15.71%
$2.22
ABAT
-21.00%
$8.94
QBTS
-10.47%
$40.08
CIFR
-10.98%
$18.72
CRML
-14.52%
$19.42
QS
-12.89%
$15.54
QSI
-3.23%
$2.54
RF
-5.98%
$23.26
RGTZ
+30.51%
$11.35
UUUU
-12.80%
$21.79
QUBT
-12.12%
$18.65
KEY
-5.35%
$16.78
MASK
+18.73%
$0.57
HBAN
-5.00%
$15.39
IREN
-8.94%
$61.89
SNAP
-2.46%
$7.71
SOUN
-2.99%
$20.76
CLSK
-13.92%
$19.97
T
+0.46%
$26.19
SMR
-10.87%
$47.62
RMBL
+60.50%
$3.21
AAPL
-0.75%
$247.45
GRAB
-3.54%
$5.71
PLTR
-0.74%
$178.28
ASST
-11.57%
$0.84
ADD
-25.47%
$0.05
WOK
+3.29%
$0.05
AUUD
+0.97%
$2.06
NOK
+0.53%
$5.68
WULF
-9.53%
$13.99
BAC
-4.03%
$50.17
MU
+4.60%
$200.77
APLD
-1.69%
$37.11
IONQ
-9.33%
$65.65
NEHC
+9.12%
$3.35
PFE
-0.59%
$24.24
SRM
+53.27%
$10.30
SOND
+78.80%
$1.64
BMNR
-4.90%
$51.16
WTO
-88.69%
$0.13
TOVX
-47.86%
$0.43
KDLY
+1.29%
$0.79
SLNH
-1.39%
$4.23
SATL
-29.71%
$2.91
JBLU
-4.94%
$4.70
AMC
-2.12%
$2.76
AMZN
-0.81%
$213.82
HIMS
-6.07%
$58.94
ELWS
+38.58%
$5.09
VHAI
-20.00%
$0.00
VIVK
+4.67%
$0.30
YYAI
-10.71%
$0.12
BURU
+1.07%
$0.34
EPWK
+26.46%
$0.09
NVDA
-0.11%
$179.83
BITF
-18.39%
$5.28
RXRX
-7.21%
$6.29
CGBS
-39.47%
$0.03
IVF
+153.11%
$1.90
PLUG
-8.70%
$3.51
ADAP
+6.57%
$0.19
BYND
-22.39%
$0.52
YDKG
-54.14%
$0.08
NVTS
+3.10%
$15.63
RGTI
-14.85%
$47.97
DNN
-2.83%
$3.08
LAES
-2.09%
$7.49
NIO
-1.09%
$6.74
MIRA
+49.24%
$1.97
SCNX
-20.41%
$0.56
F
-0.27%
$11.72
BBD
+1.71%
$3.25
WHWK
+27.64%
$2.68
ACHR
-8.90%
$11.87
TLRY
-8.33%
$1.54
KVUE
-13.43%
$14.07
TSLA
-1.47%
$428.75
ONDS
-13.77%
$8.19
IONZ
+18.46%
$3.41
AXDX
-61.36%
$0.03
INTC
-1.10%
$36.74
ETHD
+6.47%
$3.78
DFLI
-32.52%
$1.32
CAN
-14.28%
$1.68
HPE
-10.09%
$22.51
AMD
-1.33%
$235.40
SOFI
-6.13%
$26.31
GDXD
-7.91%
$0.61
RIG
-3.00%
$3.21
MARA
-11.62%
$20.18
CLF
-3.39%
$13.47
GNPX
-43.15%
$0.47
BTG
+3.96%
$5.89
FEMY
+33.89%
$0.73
VSEE
-8.56%
$0.54
BTBT
-8.99%
$3.69
AAL
-6.00%
$11.75
RR
-7.95%
$5.67
GPUS
-6.14%
$0.36
LGCB
+19.39%
$1.97
NAK
-15.71%
$2.22
ABAT
-21.00%
$8.94
QBTS
-10.47%
$40.08
CIFR
-10.98%
$18.72
CRML
-14.52%
$19.42
QS
-12.89%
$15.54
QSI
-3.23%
$2.54
RF
-5.98%
$23.26
RGTZ
+30.51%
$11.35
UUUU
-12.80%
$21.79
QUBT
-12.12%
$18.65
KEY
-5.35%
$16.78
MASK
+18.73%
$0.57
HBAN
-5.00%
$15.39
IREN
-8.94%
$61.89
SNAP
-2.46%
$7.71
SOUN
-2.99%
$20.76
CLSK
-13.92%
$19.97
T
+0.46%
$26.19
SMR
-10.87%
$47.62
RMBL
+60.50%
$3.21
AAPL
-0.75%
$247.45
GRAB
-3.54%
$5.71
PLTR
-0.74%
$178.28
ASST
-11.57%
$0.84
ADD
-25.47%
$0.05
WOK
+3.29%
$0.05
AUUD
+0.97%
$2.06
NOK
+0.53%
$5.68
WULF
-9.53%
$13.99
BAC
-4.03%
$50.17
MU
+4.60%
$200.77
APLD
-1.69%
$37.11
IONQ
-9.33%
$65.65
NEHC
+9.12%
$3.35
PFE
-0.59%
$24.24
SRM
+53.27%
$10.30
SOND
+78.80%
$1.64
BMNR
-4.90%
$51.16
WTO
-88.69%
$0.13
TOVX
-47.86%
$0.43
KDLY
+1.29%
$0.79
SLNH
-1.39%
$4.23
SATL
-29.71%
$2.91
JBLU
-4.94%
$4.70
AMC
-2.12%
$2.76
AMZN
-0.81%
$213.82
HIMS
-6.07%
$58.94
ELWS
+38.58%
$5.09

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.